-------------------------------------------------------------------------
Revenue from continuing
operations
Nucryst Pharmaceuticals $ 5,466 $ 7,839 $ 15,428 $ 20,656
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(Loss) income from continuing
operations
Nucryst Pharmaceuticals $ (114) $ (2,479) $ (4,133) $ (7,980)
Other (including corporate
costs) (1,737) (6,294) 3,622 3,984
-------------------------------------------------------------------------
Loss from continuing operations $(1,851) $ (8,773) $ (511) $ (3,996)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Consolidated Balance Sheets September December
30, 2008 31, 2007
-----------------------------------------------------
Cash and cash equivalents $ 39,147 $ 30,993
Current assets 50,249 51,561
Other assets 23,211 31,826
Current liabilities 11,141 8,461
Shareholders' equity 44,989 56,371
| SOURCE Westaim Corporation Copyright©2008 PR Newswire. All rights reserved |